Ayala Pharmaceuticals Inc

NASDAQ:AYLA   2:59:51 PM EDT
0.60
-0.02 (-3.10%)
6:29:53 PM EDT: $0.61 0.00 (0.70%)
Products

Ayala Pharmaceuticals Announces Fast Track Designation Granted By Us FDA For Al102 In Progressing Desmoid Tumors

Published: 09/27/2022 13:43 GMT
Ayala Pharmaceuticals Inc (AYLA) - Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for Al102 in Progressing Desmoid Tumors.
Ayala Pharmaceuticals Inc - Al102 is Being Evaluated in Ongoing Ringside Pivotal Phase 2/3 Clinical Trial in Desmoid Tumors.
Ayala Pharmaceuticals Inc - Al102 Was Well Tolerated.
Ayala Pharmaceuticals Inc - Company Has Initiated Part B of Ringside (phase 3), and is Enrolling Patients in an Open Label Extension Study.